GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » EPS without NRI

Quanterix (Quanterix) EPS without NRI : $-0.83 (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Quanterix EPS without NRI?

Quanterix's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.30. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.83.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 8.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Quanterix's EPS without NRI or its related term are showing as below:

QTRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -13.3   Med: -4.15   Max: 49.5
Current: 8.2

During the past 9 years, Quanterix's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 49.50% per year. The lowest was -13.30% per year. And the median was -4.15% per year.

QTRX's 3-Year EPS without NRI Growth Rate is ranked worse than
51.77% of 707 companies
in the Medical Devices & Instruments industry
Industry Median: 9.4 vs QTRX: 8.20

Quanterix's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.33. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.86.

Quanterix's EPS (Basic) for the three months ended in Dec. 2023 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.86.


Quanterix EPS without NRI Historical Data

The historical data trend for Quanterix's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix EPS without NRI Chart

Quanterix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -1.63 -1.07 -1.60 -1.98 -0.83

Quanterix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.16 -0.16 -0.21 -0.30

Competitive Comparison of Quanterix's EPS without NRI

For the Medical Devices subindustry, Quanterix's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quanterix's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quanterix's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Quanterix's PE Ratio without NRI falls into.



Quanterix EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quanterix  (NAS:QTRX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Quanterix EPS without NRI Related Terms

Thank you for viewing the detailed overview of Quanterix's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Quanterix (Quanterix) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlesex Turnpike, Billerica, MA, USA, 01821
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Executives
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly director C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram officer: Chief Financial Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser director 561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle officer: CFO and Treasurer C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue officer: President, Quanterix & Dx C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka director 2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
John J Fry officer: General Counsel & Secretary 8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky director, officer: EC, President & CEO 68 ELM STREET, HOPKINTON MA 01748
Karen Flynn director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy officer: SVP R&D and CTO C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon officer: Sr VP, Stgc Mrktg & Assay Tech 113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421